Voltar para listagem
Autor(a):

Laço Rosa

Data do Post
23/08/2018
/

Ribociclib is released by ANVISA

The drug Ribociclib was previously approved by the FDA, a US health agency, and has just been approved by ANVISA in Brazil.

It is an oral drug that has the potential to benefit patients with advanced breast cancer.

How does it work?

According to Sérgio Simon, President of the Brazilian Society of Clinical Oncology, Ribociclib acts in the body inhibiting the action of proteins responsible for the multiplication of cancer cells. Consequently, the tumor stops growing and gradually begins to regress,.

It is indicated that the use of the drug is done in conjunction with the hormone therapy, since both types of treatment delay the multiplication of the cells.

For whom is it indicated?

This type of treatment is indicated for patients with advanced breast cancer, with receptors for hormones (RH +) and HER2-. These characteristics can be determined from diagnostic tests and consist of 69% of cases of breast tumors.

Is it already available?

The drug is expected to be available for purchase by the end of the year.

Tests with Ribociclib will continue to be conducted to determine new data on drug efficacy.

 

Source: SBOC / Health Portal